Helena Iznardo Ruiz

Dr. Helena Iznardo Ruiz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HRHelena Iznardo Ruiz
Helena Iznardo Ruiz
LPLuis Puig
Luis Puig
Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.

Verified
Journal Article
Open access
PDF file
HRHelena Iznardo Ruiz
Helena Iznardo Ruiz
LPLuis Puig
Luis Puig
The interleukin-1 (IL-1) family is involved in the correct functioning and regulation of the innate immune system, linking innate and adaptative immune responses. This complex family is composed by several cytokines, receptors, and co-receptors, all working in a balanced way to maintain homeostasis. Dysregulation of these processes results in tissue inflammation and is involved in the pathogenesis of common inflammatory dermatoses such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. Therefore, therapeutic targeting of IL-1 pathways has been studied, and several monoclonal antibodies are currently being assessed in clinical trials. So far, promising results have been obtained with anti-IL-36R spesolimab and imsidolimab in pustular psoriasis, and their efficacy is being tested in other conditions.

1 January 2021 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
PDF file
HRHelena Iznardo Ruiz
Helena Iznardo Ruiz
LPLuis Puig
Luis Puig
Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologically active, but IL-17F is also over-expressed in skin and synovial tissues of patients with these diseases. Many therapeutic advances have been made in the past years, but some needs remain unmet. Dual inhibitor and bispecific antibodies simultaneously targeting IL-17A and IL-17F could provide better disease control. Herein we review current evidence on bimekizumab and sonelokimab. The antigen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelokimab is a trivalent nanobody targeting IL-17A and IL-17F; phase I and II studies with this molecule have yielded promising results in psoriasis.

23 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HRHelena Iznardo Ruiz
Helena Iznardo Ruiz
EREsther Roé
Esther Roé
Esther Serra-BaldrichEsther Serra-Baldrich
Esther Serra-Baldrich
LPLuis Puig
Luis Puig
Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62.9% (95% CrI 42.5–79.9%) for abrocitinib 200 mg and 43.0% (95% CrI 24.8–64.0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.

23 April 2020 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
VDVictoria L. Dávila‐Osorio
Victoria L. Dávila‐Osorio
HRHelena Iznardo Ruiz
Helena Iznardo Ruiz
EREsther Roé
Esther Roé
LPLluis Puig
Lluis Puig
EBEulalia Baselga
Eulalia Baselga

9 September 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
CMCristina Muniesa
Cristina Muniesa
FGFernando Gallardo
Fernando Gallardo
IGIgnacio García‐Doval
Ignacio García‐Doval
MEM. Teresa Estrach
M. Teresa Estrach
ACAndrea Combalia
Andrea Combalia
OSOctavio Servitje
Octavio Servitje